Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Padcev | enfortumab vedotin | Metastatic urothelial cancer | Pending | |||
| Venclexta | venetoclax | Chronic lymphocytic leukemia (CLL). | Pending | |||
| Mifegymiso | Mifepristone and misoprostol | Medical termination of pregnancy (gestational age up to 49 days) | Withdrawn | |||
| Praxbind | Idarucizumab (Drug Plan Submission) | Reversal of dabigatran anticoagulant effects | Withdrawn | |||
| Venclexta | Venetoclax | Withdrawn | ||||
| Cyramza | Ramucirumab | Cancelled | ||||
| Adcetris | Brentuximab vedotin | Withdrawn | ||||
| Livmarli | maralixibat | Alagille syndrome | Active | |||
| Leqvio | inclisiran | Primary hypercholesterolemia | Active | |||
| Dificid | fidaxomicin | Clostridium difficile infection | Active |
Last Updated : May 9, 2024